← Back to Search

Ultrasound Therapy

Transcranial MRgFUS for Movement Disorders

N/A
Waitlist Available
Led By Andres Lozano, MD
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the time of exablate procedure
Awards & highlights

Summary

This trial will test whether a new MRI-guided procedure can help people with hard-to-treat movement disorders by targeting areas of the brain responsible for the symptoms.

Eligible Conditions
  • Tardive Dyskinesia
  • Wilson's Disease
  • Parkinson's Disease
  • Holmes Tremor
  • Essential Tremor
  • Movement Disorders
  • Huntington's Disease
  • Dystonia
  • Orofacial Dyskinesia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the time of exablate procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the time of exablate procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Severity of Device and Procedure Related Complications

Trial Design

1Treatment groups
Experimental Treatment
Group I: Transcranial ExAblate SystemExperimental Treatment1 Intervention
Transcranial ExAblate System (MRgFUS)

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
89 Previous Clinical Trials
3,704 Total Patients Enrolled
Andres Lozano, MDPrincipal InvestigatorSunnybrook Health Sciences Centre
1 Previous Clinical Trials
10 Total Patients Enrolled

Media Library

ExAblate Transcranial MRgFUS (Ultrasound Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02252380 — N/A
Tardive Dyskinesia Research Study Groups: Transcranial ExAblate System
Tardive Dyskinesia Clinical Trial 2023: ExAblate Transcranial MRgFUS Highlights & Side Effects. Trial Name: NCT02252380 — N/A
ExAblate Transcranial MRgFUS (Ultrasound Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02252380 — N/A
~1 spots leftby Jul 2025